5 terminated, 3 completed, 3 recruiting, 3 withdrawn. 10 Phase 2, 5 Phase 3, 3 Phase 1, 1 Phase 4.
Follow Cannabidiol Oral Solution: new trials by email Literature Review of Cannabidiol Oral Solution trials Research Report on Cannabidiol Oral Solution
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS Cannabidiol Oral Solution - Lennox-Gastaut Syndrome | Phase 4 | Not yet recruiting | Jazz Pharmaceuticals | 40 | 2026-11-18 | 2026-10-22 |
| CBD for Pain Following Orthopedic Shoulder Surgery Epidiolex, Placebo oral solution - Shoulder Osteoarthritis, Rotator Cuff Injuries | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 80 | 2024-05-24 | 2026-04-16 |
| Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy Cannabidiol oral solution - Epilepsy, Rare Diseases | Phase 2 | Active not recruiting | Meyer Children's Hospital IRCCS | 30 | 2024-03-14 | 2026-10-09 |
| SCORE Emerging Adult Cannabis Use & Stress Cannabidiol oral solution, Placebo - Cannabis Use Disorder | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 148 | 2023-11-01 | 2025-11-05 |
| Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder Cannabidiol oral solution, Placebo - Social Anxiety Disorder | Phase 2 | Completed | EmpowerPharm Inc. | 239 | 2022-10-27 | 2024-11-21 |
| Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis Cannabidiol oral solution - Early Psychosis | Phase 3 | Recruiting | University of California, San Diego | 120 | 2022-06-01 | 2026-01-08 |
| CBD for Sleep in People With HIV Cannabidiol oral solution, Inert sesame seed oil - Sleep Disturbance | Phase 2 | Withdrawn | Mariana Cherner, PhD | 2021-04-01 | 2024-05-10 | |
| A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome Cannabidiol Oral Solution - Prader-Willi Syndrome | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 2 | 2018-09-06 | 2023-06-22 |
| A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms Cannabidiol Oral Solution, Placebo, Vigabatrin - Infantile Spasm | Phase 3 | Terminated | Radius Pharmaceuticals, Inc. | 2 | 2018-09-05 | 2023-06-07 |
| Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Cannabidiol Oral Solution - Childhood Absence Epilepsy | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 11 | 2018-02-20 | 2023-06-18 |
| Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome Cannabidiol Oral Solution, Placebo Solution - Lennox-Gastaut Syndrome | Phase 3 | Withdrawn | INSYS Therapeutics Inc | 2017-12-30 | 2018-01-04 | |
| Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome Cannabidiol Oral Solution, Placebo Solution - Dravet Syndrome | Phase 3 | Withdrawn | INSYS Therapeutics Inc | 2017-12-30 | 2018-01-04 | |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Cannabidiol Oral Solution - Childhood Absence Epilepsy | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 20 | 2017-12-29 | 2023-07-21 |
| Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms Cannabidiol Oral Solution - Spasms, Infantile | Phase 2 | Terminated | INSYS Therapeutics Inc | 9 | 2016-01-27 | 2018-09-19 |
| Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder Cannabidiol Oral Solution - Seizures | Phase 3 | Completed | INSYS Therapeutics Inc | 52 | 2016-01-08 | 2018-07-26 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders Cannabidiol Oral Solution - Seizures | Phase 1 / Phase 2 | Completed | INSYS Therapeutics Inc | 61 | 2015-04-13 | 2017-06-23 |
| Expanded Use of Cannabidiol Oral Solution Cannabidiol oral solution - Refractory Epilepsy | No longer available | MultiCare Health System Research Institute | 2024-02-02 |
Lennox Gastaut Syndrome (3) · Drug Resistant Epilepsy (2) · Epilepsies, Myoclonic (2) · Epilepsy, Absence (2) · Seizures (2) · Spasms, Infantile (2) · Coitus (1) · Epilepsy (1) · Marijuana Abuse (1) · Parasomnias (1) · Phobia, Social (1) · Prader-Willi Syndrome (1) · Psychotic Disorders (1) · Rare Diseases (1) · Rotator Cuff Injuries (1)
INSYS Therapeutics Inc (5) · Radius Pharmaceuticals, Inc. (4) · EmpowerPharm Inc. (1) · Jazz Pharmaceuticals (1) · Mariana Cherner, PhD (1) · Medical University of South Carolina (1) · Meyer Children's Hospital IRCCS (1) · MultiCare Health System Research Institute (1) · The Methodist Hospital Research Institute (1) · University of California, San Diego (1)
United States (13) · Italy (1)
Neha Parikh (5) · Ahmed Elkashef, MD (3) · Kevin M Gray, M.D. (1) · Kristin Cadenhead, MD (1) · Mariana Cherner, PhD (1) · Patrick McCulloch, MD (1)
R21DA053160 (1)